Literature DB >> 11300381

Spasmolytic effect of magnesium sulfate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs.

H Yoshioka1, K Hirota, T Sato, Y Hashimoto, H Ishihara, A Matsuki.   

Abstract

BACKGROUND: Magnesium (Mg2+) has relaxant effects on histamine-induced bronchoconstriction. In addition, Mg2+ has been reported to reduce vascular smooth muscle tone and be clinically useful for treatment of persistent pulmonary hypertension of the newborn. In this study, we evaluated the relaxant effect of Mg2+ on serotonin (5HT)-induced bronchoconstriction and pulmonary hypertension.
METHODS: Seven mongrel dogs were anesthetized with pentobarbital (30 mg x kg(-1) + 2 mg x kg(-1) x h(-1)) and paralyzed by pancuronium (0.2 mg x kg(-1) x h(-1)). Bronchoconstriction and pulmonary hypertension were elicited with 5HT (10 microg x kg(-1) + 1 mg x kg(-1) x h(-1)). Airway caliber was evaluated by changes in bronchial cross-sectional area (BCA) of the 3rd bronchial bifurcation measured by a fiberoptic bronchoscope method as previously reported. Pulmonary hypertension was assessed by changes in pulmonary vascular resistance (PVR). The BCA and PVR were expressed as per cent of the basal level. Thirty minutes after start of 5HT infusion, magnesium sulfate (MgSO4): 0 (saline), 1, 10, 100 and 1000 micromol x kg(-1) was given i.v.. Arterial blood was also collected to measure plasma level of Mg2+ and catecholamines.
RESULTS: 5HT increased %PVR to 163+/-25% and decreased % BCA by 39.2+/-4.5%. Plasma level of Mg2+ following MgSO4 1000 micromol x kg(-1) i.v. exceeded its toxic level. The ED50s of MgSO4 (dose producing 50% relaxation of maximal constriction) was 47.8 micromol x kg(-1) and 1.09 mmol x kg(-1) for pulmonary hypertension and bronchoconstriction, respectively. The ratio of %PVR to %SVR was about 1.0 after MgSO4 0-100 micromol x kg(-1) i.v., although the ratio significantly increased after 1000 micromol x kg(-1) i.v..
CONCLUSION: In dogs, 5HT-induced pulmonary hypertension but not bronchoconstriction was significantly reduced by an iv bolus of MgSO4, resulting in a plasma concentration within the assumed therapeutic level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300381     DOI: 10.1034/j.1399-6576.2001.045004435.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  4 in total

1.  Feasibility of short-term infusion of magnesium sulfate in pediatric patients with status asthmaticus.

Authors:  Jose Irazuzta; Tosha Egelund; Sarah K Wassil; Christian Hampp
Journal:  J Pediatr Pharmacol Ther       Date:  2012-04

2.  Comparison of Two High-Dose Magnesium Infusion Regimens in the Treatment of Status Asthmaticus.

Authors:  Danish Vaiyani; Jose E Irazuzta
Journal:  J Pediatr Pharmacol Ther       Date:  2016 May-Jun

3.  High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study.

Authors:  Tosha A Egelund; Sarah K Wassil; Elisa M Edwards; Stephan Linden; Jose E Irazuzta
Journal:  Intensive Care Med       Date:  2012-11-06       Impact factor: 17.440

4.  Magnesium Sulfate Mitigates the Progression of Monocrotaline Pulmonary Hypertension in Rats.

Authors:  Chao-Yuan Chang; Hung-Jen Shih; I-Tao Huang; Pei-Shan Tsai; Kung-Yen Chen; Chun-Jen Huang
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.